Medication and sexual side effects

Why this matters

Medication is one of the most common and most reversible causes of sexual difficulty, and one of the least discussed. Prescribers frequently do not mention it, patients frequently do not raise it, and the result is people who stop necessary medication without telling anyone — a significant safety issue in its own right, particularly with antidepressants and antihypertensives.

Nothing here is a reason to stop a prescribed medicine. It is a reason to have the conversation.

Antidepressants

The largest single category. Montejo et al. (2001), prospectively assessing 1,022 patients, found sexual dysfunction in 59 percent overall on SSRIs and SNRIs — higher than the rates in original trial reporting, which relied on spontaneous reporting rather than direct questioning.

Effects: delayed or absent orgasm (the most common), reduced desire, reduced arousal and lubrication, erectile difficulty, and genital numbness.

Options to discuss with a prescriber: waiting, since some effects settle over months; dose reduction; switching to bupropion, mirtazapine or vortioxetine; adding bupropion; adding a PDE5 inhibitor, which has trial evidence for SSRI-associated erectile and orgasmic difficulty in both men and women; or scheduled drug holidays, which are used but carry discontinuation and relapse risk and are not appropriate with fluoxetine.

Untreated depression itself reduces sexual function substantially. Distinguishing the illness from the treatment usually requires asking whether function was affected before starting.

Post-SSRI sexual dysfunction (PSSD) — persistent genital numbness, reduced libido and orgasmic difficulty continuing after stopping — was formally recognised by the European Medicines Agency in 2019 as a possible long-lasting effect. It appears rare, mechanisms are not established, and no treatment has proven efficacy. It is real, it is acknowledged by regulators, and it should not be dismissed.

Cardiovascular medication

• Thiazide diuretics — well-documented erectile dysfunction; among the more common culprits.
• Beta blockers — erectile dysfunction and reduced desire; older agents such as propranolol and atenolol more than nebivolol, which has nitric-oxide-mediated effects and may be neutral or beneficial.
• Spironolactone — anti-androgenic; reduced desire, erectile dysfunction, breast tenderness.
• ACE inhibitors, ARBs and calcium channel blockers — generally neutral, and ARBs have some evidence of improvement.

Since hypertension itself causes erectile dysfunction, switching class rather than stopping treatment is usually the answer.

Hormonal and urological

• Finasteride and dutasteride — reduced libido, erectile dysfunction and ejaculatory disorder in a minority. Persistent symptoms after stopping (post-finasteride syndrome) are reported and are subject to regulatory label warnings in several countries; prevalence and mechanism remain contested.
• Tamsulosin and alpha blockers — retrograde or absent ejaculation, common and harmless but alarming if unexpected.
• Anti-androgen therapy for prostate cancer — profound loss of desire, erectile function and often orgasm. Should be discussed before starting, alongside penile rehabilitation options.
• Hormonal contraception — evidence is genuinely mixed. Most large studies find no average effect on desire; a subset of users experience clear reduction, associated in some work with reduced free testosterone. An individual's experience is valid even where the population average shows nothing, and switching formulation or method is reasonable.

Other categories

• Antipsychotics — those raising prolactin most (risperidone, paliperidone, haloperidone, amisulpride) cause the most sexual dysfunction. Aripiprazole and quetiapine are lower. Prolactin should be checked when symptoms appear.
• Opioids — suppress the hypothalamic-pituitary-gonadal axis, causing hypogonadism with long-term use. Under-recognised and testable.
• Antiepileptics — enzyme-inducing agents such as carbamazepine reduce free testosterone; they also reduce hormonal contraceptive efficacy.
• Antihistamines — dryness, including vaginal, with regular use.
• Statins — evidence is mixed; some studies suggest modest improvement via vascular effects rather than harm.
• Chemotherapy — mucositis, dryness, early menopause, fertility loss. Fertility preservation should be discussed before starting, not after.
• Alcohol — acutely impairs arousal and orgasm; chronically causes hypogonadism and neuropathy.

How to raise it

• "Since starting [medicine], I've noticed [specific change]. Is that a known effect, and is there an alternative?"
• Be specific about which part is affected — desire, arousal, orgasm, pain — because the answer differs.
• Ask directly about switching, dose, timing and add-on options.
• Do not stop medication first and report afterwards.

Sources

• Montejo AL et al. "Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients." Journal of Clinical Psychiatry, 2001.
• Serretti A, Chiesa A. "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis." Journal of Clinical Psychopharmacology, 2009.
• European Medicines Agency, PRAC. Recommendation on persistent sexual dysfunction after SSRI/SNRI discontinuation, 2019.
• Manolis A, Doumas M. "Sexual dysfunction: the prima ballerina of hypertension-related quality-of-life complications." Journal of Hypertension, 2008.
• Traish AM et al. Reviews on 5-alpha-reductase inhibitors and persistent sexual side effects.
• Pastuszak AW et al. and reviews on opioid-induced androgen deficiency.
• Zimmerman Y et al. "The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis." Human Reproduction Update, 2014.

Last reviewed: August 2026.